rs794727076
Positions:
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BP4_StrongBS2
The NM_006950.3(SYN1):c.1615G>A(p.Gly539Ser) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000263 in 1,022,489 control chromosomes in the GnomAD database, including 1 homozygotes. There are 78 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.00052 ( 0 hom., 17 hem., cov: 23)
Exomes 𝑓: 0.00023 ( 1 hom. 61 hem. )
Consequence
SYN1
NM_006950.3 missense
NM_006950.3 missense
Scores
1
3
13
Clinical Significance
Conservation
PhyloP100: 1.47
Genes affected
SYN1 (HGNC:11494): (synapsin I) This gene is a member of the synapsin gene family. Synapsins encode neuronal phosphoproteins which associate with the cytoplasmic surface of synaptic vesicles. Family members are characterized by common protein domains, and they are implicated in synaptogenesis and the modulation of neurotransmitter release, suggesting a potential role in several neuropsychiatric diseases. This member of the synapsin family plays a role in regulation of axonogenesis and synaptogenesis. The protein encoded serves as a substrate for several different protein kinases and phosphorylation may function in the regulation of this protein in the nerve terminal. Mutations in this gene may be associated with X-linked disorders with primary neuronal degeneration such as Rett syndrome. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -8 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.0074963868).
BS2
High Hemizygotes in GnomAd4 at 17 XL gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SYN1 | NM_006950.3 | c.1615G>A | p.Gly539Ser | missense_variant | 12/13 | ENST00000295987.13 | NP_008881.2 | |
SYN1 | NM_133499.2 | c.1615G>A | p.Gly539Ser | missense_variant | 12/13 | NP_598006.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SYN1 | ENST00000295987.13 | c.1615G>A | p.Gly539Ser | missense_variant | 12/13 | 2 | NM_006950.3 | ENSP00000295987.7 | ||
SYN1 | ENST00000340666.5 | c.1615G>A | p.Gly539Ser | missense_variant | 12/13 | 1 | ENSP00000343206.4 | |||
SYN1 | ENST00000640721.1 | c.70+319G>A | intron_variant | 5 | ENSP00000492857.1 |
Frequencies
GnomAD3 genomes AF: 0.000524 AC: 58AN: 110675Hom.: 0 Cov.: 23 AF XY: 0.000510 AC XY: 17AN XY: 33365
GnomAD3 genomes
AF:
AC:
58
AN:
110675
Hom.:
Cov.:
23
AF XY:
AC XY:
17
AN XY:
33365
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000522 AC: 2AN: 3831Hom.: 0 AF XY: 0.00346 AC XY: 1AN XY: 289
GnomAD3 exomes
AF:
AC:
2
AN:
3831
Hom.:
AF XY:
AC XY:
1
AN XY:
289
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000231 AC: 211AN: 911787Hom.: 1 Cov.: 32 AF XY: 0.000214 AC XY: 61AN XY: 284817
GnomAD4 exome
AF:
AC:
211
AN:
911787
Hom.:
Cov.:
32
AF XY:
AC XY:
61
AN XY:
284817
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000524 AC: 58AN: 110702Hom.: 0 Cov.: 23 AF XY: 0.000509 AC XY: 17AN XY: 33412
GnomAD4 genome
AF:
AC:
58
AN:
110702
Hom.:
Cov.:
23
AF XY:
AC XY:
17
AN XY:
33412
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:4Benign:4
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Uncertain:3Benign:2
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Dec 22, 2017 | - - |
Likely benign, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Athena Diagnostics | Feb 12, 2020 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Feb 27, 2015 | The G539S missense change has not been published as a mutation, nor has it been reported as a benign polymorphism to our knowledge. It was not observed in approximately 1,400 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The G539S variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. However, this substitution alters a position that is poorly conserved across species, and in silico analysis predicts G539S likely does not alter the protein structure/function. The variant is found in EPILEPSY panel(s). - |
Likely benign, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | May 19, 2020 | The c.1615G>A (p.G539S) alteration is located in exon 12 (coding exon 12) of the SYN1 gene. This alteration results from a G to A substitution at nucleotide position 1615, causing the glycine (G) at amino acid position 539 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
SYN1-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Aug 03, 2023 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Epilepsy, X-linked 1, with variable learning disabilities and behavior disorders Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 08, 2023 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
T;.
FATHMM_MKL
Benign
N
LIST_S2
Benign
T;T
M_CAP
Uncertain
D
MetaRNN
Benign
T;T
MetaSVM
Benign
T
MutationAssessor
Benign
N;N
PrimateAI
Pathogenic
D
PROVEAN
Benign
N;N
REVEL
Benign
Sift
Uncertain
D;D
Sift4G
Benign
T;T
Polyphen
B;B
Vest4
MutPred
Gain of phosphorylation at G539 (P = 0.0062);Gain of phosphorylation at G539 (P = 0.0062);
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at